EDUCATION AND TRAINING

Size: px

Start display at page:

Download "EDUCATION AND TRAINING"

Buck Townsend
6 years ago
Views:

1 Monika L. Burness, M.D. Assistant Professor, Internal Medicine Division of Hematology/Oncology University of Michigan Medical School University of Michigan Comprehensive Cancer Center Office: NCRC, B26/319S Ann Arbor, MI ; EDUCATION AND TRAINING 08/ /2000 Pennsylvania State University, Schreyer Honors College, Bachelor of Science in Biochemistry and Molecular Biology, Honors in Sociology 08/ /2005 Pennsylvania State University College of Medicine, M.D. 07/ /2008 The Johns Hopkins Hospital, Osler Medical Service, Internal Medicine Internship and Residency 07/ /2011 University of Chicago Medical Center, Hematology/Oncology Fellowship CERTIFICATIONS AND LICENSURE 2008 American Board of Internal Medicine, Board Certified in Internal Medicine 2011 American Board of Internal Medicine, Board Certified in Medical Oncology 2011 Licensed Physician, State of Illinois, # Licensed Physician, State of Michigan, # ACADEMIC APPOINTMENTS 07/ /2012 Clinical Instructor in Breast Oncology, University of Chicago Medical Center 08/ /2017 Clinical Lecturer, Internal Medicine, Hematology/Oncology, University of Michigan Medical School 10/2017-present RESEARCH EXPERIENCE Assistant Professor, Internal Medicine, Hematology/Oncology, University of Michigan Medical School 06/ /2001 National Institutes of Health Summer Research Fellowship Program Research Project: Effect of melanoma cell secreted factors on endothelial cell cytokine production Laboratory of Dr. H. Richard Alexander, Surgery Branch, NCI Monika L. Burness, MD 2/6/2017 1

2 08/ /2004 Howard Hughes Medical Institute/National Institutes of Health Research Scholars Program Research Projects: Role of ADAM10 and fractalkine in cell migration within the tumor microenvironment; Gene expression profiling of different metastatic sites in colorectal cancer Laboratory of Dr. H. Richard Alexander, Surgery Branch, NCI 07/ /2012 University of Chicago, Postdoctoral Fellow and Advanced Research Fellow Areas of Expertise: Breast Cancer Metastasis, Metastatic Tumor Niches, Intravital Microscopy Research Project: Role of CXCR4 in homing of breast cancer cells to bone marrow microenvironment Laboratory of Dr. Dorothy Sipkins RESEARCH GRANTS Active research grants: Gift The Pink Rocks Foundation Title: Improving effectiveness of PARP inhibitors for treatment of triple negative breast cancer. Total Project Period: 01/01/ /31/2021 Annual Direct Cost: $20,000 Lefkofsky Family Foundation Scholar Award - `University of Michigan Health System Title: N/A Total Project Period 03/31/ /01/2018 Total Direct Cost: $250,000 Study Agreement (Burness) Paraxel/Pfizer Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Fulvestrant (Fasolodex) With or Without PD (Palbociclib) Goserelin in Women with Hormone Receptor-Positive, HER2-Positive, HER2-Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy Total Project Period: 01/01/ /31/2019 Total Direct Cost: $180,593 Study Agreement (Burness) (TRIO)/Pfizer Effort: 0.12 Calendar Months Title: Translational Research in Oncology - A Randomized, Multicenter, Double-Blind Phase 3 Study of PD (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women with ER(+), HER2(-) Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment For Advanced Disease Dates: 07/22/ /14/2018 Total Direct Cost: $185,975 Study Agreement (Burness) Genentech Inc. Title: A Phase 1 Multi-Center Trial of Trastuzumab in Combination with Tocilizumab in Patients Monika L. Burness, MD 11/14/17 2

3 with Metastatic Her2 Positive Breast Cancer Resistant to Trastuzumab Total Project Period: 05/01/ /30/2019 Total Direct Cost: $483,399 I.D. Number: CCR Susan G. Komen Foundation Effort: 5.4 Calendar Months Title: Role of Cancer Stem Cells in Mediating Resistance to DNA Repair Targeting Therapy Total Project Period: 10/04/ /03/2020 Annual Direct Cost: $120,000 Pending research grants: I.D. Number: Grant (Luo) Department of Defense Co-Investigator Effort: 0.6 Calendar Months Title: Targeting Metabolic Vulnerabilities of Distinct Breast Cancer Stem Cell States Using Pro- Oxidant Based Therapeutics Annual Direct Cost: $250,000 Completed research grants: Dr. Frank Limpert Clinical Research Award - University of Michigan Comprehensive Cancer Center Title: N/A Total Project Period: 11/01/ /31/2016 I.D. Number: N021378(contract: Wicha, PI) MedImmune Co-Investigator Effort: 0.6 Calendar Months Title: Cytokine Inhibition and CTC assay development and tumor immunotherapy of CSCs. Total Project Period: 09/01/ /31/2016 Annual Direct Cost: $225,723 I.D. Number: N (contract: Wicha, PI), Cormorant Pharmaceuticals Co-Investigator Effort: 1.2 Calendar Months Title: Assessment of the biologic effects of IL-8 inhibition in triple negative and Her2+ breast cancer stem cells and therapy responsive circulating tumor cells. Total Project Period: 08/14/ /31/2016 Annual Direct Cost: $232,251 Bench to bedside Translation Award, Michigan Institute for Clinical and Health Research Effort: 1.8 Calendar Months Title: Targeting cancer stem cells via IL-6 signaling in triple-negative breast cancer Total Project Period: 07/01/ /30/2015 Annual Direct Cost: $50,000 American Society of Clinical Oncology/Breast Cancer Research Foundation Young Investigator Award Title: Real time in vivo imaging of breast cancer metastatic to bone and importance of CXCR4 Total Project Period: 7/1/ /31/2011 University of Chicago Breast Cancer SPORE Monika L. Burness, MD 11/14/17 3

4 Sub-Investigator (PI: Dr. Dorothy Sipkins) Title: In Vivo Imaging of Metastatic Breast Cancer Cell Interactions with the Bone Marrow Total Project Period: 3/1/ /31/2010 Microenvironment NIH T32 Training Grant Award Research Fellow (PI: Dr. Funmi Olopade) Total Project Period: 7/1/2009 6/30/2010 HONORS AND AWARDS 2004 Howard Hughes Medical Institute Continuing Support Fellowship 2009 Award National Institutes of Health Clinical Loan Repayment Program (LRP) 2010 American Society of Clinical Oncology Young Investigator Award (YIA) 2014 University of Michigan Comprehensive Cancer Center Dr. Frank Limpert Clinical Research Award University of Michigan Health System Lefkofsky Family Foundation Scholar Award PROFESSIONAL SOCIETY MEMBERSHIPS 2008-present 2008-present American Association for Cancer Research American Society of Clinical Oncology TEACHING AND MENTORING 02/2011, 02/2012 Teaching Assistant, Pritzker Medical School 2 nd Year Curriculum, Breast Cancer Module/Laboratory Session Sept March 2010 Mentees: Invited Lecture, Health Studies Course #30500: Issues in Women s Health, Breast Cancer- Impact on Women and Society University of Chicago Hematology/Oncology Grand Rounds, In Viv Imaging of Metastatic Breast Cancer Interactions with the Bone Marrow Microenvironment Mallory Raymond Undergraduate, University of Chicago 2010 Florence Choo Undergraduate, University of Chicago Renee Cheng Undergraduate, University of Chicago Bonnie Liu Post-doctoral scholar, University of Michigan Leo Hernandez Oncology Fellow, University of Michigan Kelsey Kerr Undergraduate, University of Michigan Heidi Egloff Hem/Onc Fellow, University of Michigan Shadae Sutherland M.S. Candidate, Graduate, University of Michigan Monika L. Burness, MD 11/14/17 4

5 Yei-Jee Burkitt UROP Student, University of Michigan BIBLIOGRAPHY Peer-reviewed Journals and Publications: Over 494 citations; h-index 7; i10-index 7 1. Feldman ED, Weinrich DM, Carroll NM, Burness ML, Feldman AL, Turner E, Xu H, Alexander HR Jr. Interferon gamma-inducible protein 10 selectively inhibits proliferation and induces apoptosis in endothelial cells. Ann Surg Oncol Jan;13(1): PMID: Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol Dec; 14(12): PMID: Burness ML, Grushko TA, Olopade OI. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J Jan- Feb; 16(1): PMID: (No NIH support cited). 4. Burness ML, Sipkins DA. The stem cell niche in health and malignancy. Semin Cancer Biol Apr;20(2): PMID: (No NIH support cited). 5. Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant Paclitaxel: A case report. Clin Breast Cancer 2014 Sept 28. PMID: Doi /j.clbc [Epub ahead of print]. (No NIH support cited). 6. Brooks MD*, Burness ML*, Wicha MS. Therapeutic implications of cellular heterogeneity and plasticity in breast cancer. Cell Stem Cell, 2015 Sept; 17(3): PMCID: *These authors contributed equally 7. Price T, Burness M, Sivan A, Warner M, Cheng R, Lee C, Olivere L, Comatas K, Magnani J, Kim Lyerly H, Cheng Q, McCall CM, Sipkins D. Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Science Translational Medicine, 2016 May 25; 8(340): 340ra73. PMCID: Yoon HJ, Shanker A, Wang Y, Kozminsky M, Jin Q, Palanisamy N, Burness ML, Azizi E, Simeone D, Wicha MS, Kim J, Nagrath S. Efficient capture and release of circulating tumor cells by temperature-sensitive polymer-graphene oxide composite. Advanced Materials. Advanced Materials June 28; 28(24) Liu B, Burness ML, Martin-Trevino R, Guy J, Bai S, Harouaka R, Brooks M, Shang L, Fox A, Luther T, Davis A, Baker TL, Colacino J, Clouthier SG, Shao ZM, Wicha M, Liu S. RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer. Clinical Cancer Research, 2017 Jan 15;3(2): PMID: No Federal support cited. *these authors contributed equally 10. Lin E*, Rivera-Báez L*, Fouladdel, S*, Yoon H, Guthrie S, Wieger J, Deol Y, Keller E, Sahai B, Simeone D, Burness ML, Azizi E, Wicha M, Nagrath S; High Throughput Microfluidic Labyrinth for the Label Free Isolation of CTCs for Single Cell Gene Expression Profiling; Cell Systems, 2017 Sep 27; DOI: doi: /j.cels Epub 2017 Sep 20. *these authors contributed equally PMID: [PubMed in process] 11. Price TT, Burness ML, Sivan A, Warner MJ, Cheng R, Lee CH, Olivere L, Comatas K, Magnani J, Kim Lyerly H, Cheng Q, McCall CM, Sipkins DA; Dormant breast cancer Monika L. Burness, MD 11/14/17 5

6 micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med May 25; 8(340):340ra73. doi: /scitranslmed.aad4059. OMID: [PubMed indexed for MEDLINE] Non Peer-reviewed Publications: 1. Burness ML, Olopade OI. Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol May 1; 29(13): [Editorial] PMID: (No NIH support cited). Book Chapters 1. Burness ML, Van Poznak C. Metastatic breast cancer: clinical considerations. In: Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. McManus L, Mitchell R (Eds). S&T Books, Elsevier Inc., Waltham, MA. 2014, pp doi: /b x 2. McDonnell K, Burness M. Breast Cancer. In: Oncology Boards Flash Review. Worden F, Khoriaty R, Parkin B, Malhotra B (Eds). Demos Medical, New York, NY (No NIH support cited). Abstracts 1. Burness ML, Puhlmann M, Weinrich D, Turner E, Alexander HR. Selective Activation of Endothelium by Tumor Necrosis Factor (TNF) Sensitive but Not TNF Resistant Melanoma Cell Lines. Poster presentation at American Association of Cancer Research (AACR) Annual Meeting, March Burness ML, Xu H, Rosen J, Alexander HR. Identification of distinct gene expression profiles in peritoneal versus liver metastases in patients with advanced colorectal adenocarcinoma. Poster presentation at American Association of Cancer Research (AACR) Annual Meeting, April Liu Y, Hernandez L, Davis A, Wicha M, Burness M. Interleukin 6 and interleukin 8 inhibitors when used with combination with chemotherapy inhibits tumor progression in mouse model of triple-negative breast cancer. Poster presentation at American Association of Cancer Research (AACR) Annual Meeting, March Fouladdel S, Yoon HJ, Kim TH, Shi A, Luther T, Hayden J, Clouthier S, Deol Y, Burness M, Hayes D, Nagrath S, Azizi E, Wicha M. Circulating tumor cells (CTCs) isolated from patients with metastatic breast cancer utilizing a sensitive microfluidic graphene oxide (GO) nanosheet device express markers of cancer stem cells AACR, San Diego, CA. 5. Price T, Burness M, Sivan A, Cheng R, Magnani JL, Sipkins DA. Breast cancer cells metastasize to bone through E-selectin vascular gateways AACR, San Diego, CA. 6. Yajing Liu; Rachel Martin-Trevino, Li Shang, April Davis, Max S. Wicha, Suling Liu, Monika Burness. Histone Deacetylase Inhibitors Sensitize Cancer Stem Cells to PARP Inhibitors in Triple-Negative Breast Cancer AACR, Philadelphia, PA. 7. Leonel Hernandez-Aya, Yajing Liu, Kelsey Kerr, Nouri Neamati, Shuzo Tamura, Max S. Wicha, Monika L. Burness. Targeting the gp130 receptor in preclinical models of triplenegative breast cancer AACR, Philadelphia, PA. Monika L. Burness, MD 11/14/17 6

Samantha K. Holden, MD East 17th Avenue Campus Box B185 Aurora, CO Phone:

Samantha K. Holden, MD East 17th Avenue Campus Box B185 Aurora, CO Phone: EDUCATION Samantha K. Holden, MD University of Colorado Anschutz Medical Campus, Colorado Clinical and Translational Sciences Institute, Clinical Sciences Graduate Program, M.S. in Clinical Science. Expected